Back to All

PD-L1: The Story So Far

29 September, 2017

The time of the old and well-known ‘one-size-fits-all’ approach to therapy is being overtaken by precision medicine and the commercialization of multiple targeted therapies. We are now in an era in which the coexistence of diagnostics and biomarker detection on the treatment pathway is not an option, but mandatory. With regulatory authorities now favoring submission of therapy for approval alongside diagnostic test development, the importance of biomarkers and diagnostic testing for pharma companies is becoming a top priority.

One of the most talked about new biomarkers in the context of targeted therapy has been PD-L1. Diaceutics began tracking PD-L1 testing in 2015 and our observations reveal that its integration into treatment pathways and drug launch programs, as is the case with other novel biomarkers, is not without problems. The PD-L1 space, which has been particularly dynamic, has provided opportunities to undertake real-time market analysis and improve our understanding of novel biomarker adoption. Interestingly, in the first 18 months post-launch, over 70 US labs started using the test, and that number continues to grow. This indicates that PD-L1 testing has a fast-track pattern of uptake in parallel with treatment recommendations.

Our new Ebook, PD-L1: The Story So Far, tracks the evolution of PD-L1 through a series of Expert Insights written by the Diaceutics team from 2015 to 2017, and examines topics including test availability, integration alongside more established biomarkers, complementary testing and how a suboptimal PD-L1 diagnostic marketplace can lead to lost treatment opportunities. A clear theme throughout is that while precision medicine continues to progress, we still suffer from the lack of pre-launch market development of critical diagnostics, even though most of the issues surrounding PD-L1 have been seen before.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny